European Nuclear Medicine/Radiopharmaceuticals Market: Increasing Preference for Spect and PET Scans | Market overview | Forecast Analysis.

1sales@marketsandmarkets.com www.marketsandmarkets.com
EUROPEAN NUCLEAR
MEDICINE/ RADIO
PHARMACEUTICALS
MARKET
GLOBAL FORECAST TO 2020
EUROPEAN NUCLEAR MEDICINE/ RADIO PHARMACEUTICALS MARKETX
By Type {Diagnostic (Spect - Technetium, Pet- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters,
Brachytherapy – Y-90)}, By Application (Oncology, Thyroid, Cardiology)
REPORT OVERVIEW
1.1 OBJECTIVES OF THE STUDY
• To define and measure the European nuclear medicine/radiopharmaceuticals
market on the basis of type, and application
• To forecast the revenue of market segments with respect to Europe - Germany,
France, Italy, U.K., Spain, Russia and Rest of Europe.
• To identify key micromarkets1 and their drivers within the European nuclear
medicine/radiopharmaceuticals market, which are expected to show impressive
growth opportunities in the coming years
• To analyze opportunities in the market for stakeholders and provide details of
the competitive landscape for market leaders To strategically analyze the
market structure and profile the key players of the European nuclear medicine/
radiopharmaceuticals market and comprehensively analyze their core
competencies2
• To track and analyze competitive developments such as agreements and
contracts; expansion; acquisition; and market development
HEALTHCARE

1.2 MARKET DEFINITION
• Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation, used in nuclear imaging
to diagnose and treat diseases. The nuclear medicine/radiopharmaceuticals market is bifurcated into diagnostic
and therapeutic segments. Radiopharmaceuticals in the diagnostic market are categorized as SPECT and
PET, whereas radiopharmaceuticals in the therapeutic market are categorized as beta emitters, brachytherapy
isotopes, and alpha emitters.
1.3 MARKET SCOPE
• This report studies the European nuclear medicine/radiopharmaceuticals market, by type and application,
to arrive at the revenue generated in the European nuclear medicine/radiopharmaceuticals market from
2015 to 2020
• The diagnostic and therapeutic segments are considered for this market study
1.3.1 MARKETS COVERED
• FIGURE 1 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICAL MARKET SEGMENTATION
• This research report categorizes the European nuclear medicine/radiopharmaceutical market into the following
segments:
•
• Diagnostic Market
• SPECT
• Technetium-
99m
• Thallium-201
• Gallium-67
• Iodine-123
• Others
• PET
• Fluorine-18
• Rubidium-82
• Others
• Therapeutic Market
• Beta Emitters
• Iodine-131
• Samarium-153
• Rhenium-186
• Yttrium-90
• Lutetium-177
• Others
• Alpha Emitters
• Radium-223
• Brachytherapy
• Iodine-125
• Palladium-103
• Cesium-131
• Iridium-192
• Others
EUROPEAN NUCLEAR
MEDICINE MARKET,
BY TYPE
• SPECT
• PET
• Beta Emitters
• Alpha Emitters
• Brachytherapy
• SPECT
• Cardiology
• Oncology
• Neurology
• Thyroid
• Others
• PET
• Oncology
• Cardiology
• Neurology
• Thyroid
• Others
• Thyroid
• Bone Metastasis
• Lymphoma
• Endocrine Tumor
• Others
EUROPEAN NUCLEAR
MEDICINE
PROCEDURAL
VOLUMES
EUROPEAN NUCLEAR
MEDICINE MARKET,
BY APPLICATION
EUROPEAN NUCLEAR
MEDICINE MARKET,
BY COUNTRY
• Germany
• France
• Italy
• U.K.
• Spain
• Russia
• Rest of Europe (RoE)
INTRODUCTION

1.3.2 YEARS CONSIDERED FOR THE STUDY
•
2013
HISTORICAL YEAR
2014
BASE YEAR
2015-e
ESTIMATED YEAR
2020-p
PROJECTED YEAR
• Note: e-estimated, p-projected
Note: For market estimates, the calendar year has been considered, whereas for company profiles, the fiscal year has been considered.
1.4 CURRENCY
• The currency used in this report is USD, with market sizes indicated in USD Million.
• For companies reporting revenues in USD, the revenues were taken from their annual reports
• For companies reporting their revenues in other currencies, the average annual currency conversion rate
was used for the particular year to convert the value to USD
1.5 LIMITATIONS
• Some companies in this market are privately owned and their revenues are not available in the public
domain. Hence, revenues for those companies are not included in this report
• Company developments not reported in the public domain are not included in the report
1.6 STAKEHOLDERS
• Radiopharmaceutical/Radioisotope Manufacturers and Distributors
• Stable Isotope Manufacturers and Distributors
• Healthcare Institutions (Hospitals, Medical Schools, and Outpatient Clinics)
• Research and Consulting Firms
• Research Institutes
• Venture Capitalists
• Contract Manufacturing Organizations (CMOs)
• Contract Research Organizations (CROs)
INTRODUCTION

2.1 RESEARCH METHODOLOGY STEPS
• FIGURE 2 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: RESEARCH
METHODOLOGY STEPS
•
• Market classification for the European nuclear
medicine/radiopharmaceuticals market
• Technical information on the European nuclear
medicine/radiopharmaceuticals market by type, procedural volume,
application, and country
• Identification of the key players in the European nuclear
medicine/radiopharmaceuticals market
• Annual reports, SEC filings, investor presentations, and press releases
of the key industry players
• European nuclear medicine/radiopharmaceuticals market size
• Validation of market drivers, restraints, challenges, and
opportunities
• Country-wise markets with their market shares
• Market trends and forecasts
• Value validation
• European nuclear medicine/radiopharmaceuticals market
segmentation
• Top-down approach
• Bottom-up approach
• Data triangulation
• Market estimation
• Market forecast
• Qualitative and quantitative analysis
RESEARCH METHODOLOGY

2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY
2.2.1 SECONDARY RESEARCH
• Secondary sources were used to identify and collect useful information for this extensive, technical, and
commercial study of the European nuclear medicine/radiopharmaceuticals market.
• FIGURE 3 KEY DATA FROM SECONDARY SOURCES
•
PARAMETER SOURCE
MARKET SIZE
• Company Financials
• Magazines
• Journals
• Press Releases
• Paid Databases
• MarketsandMarkets Data Repository
REVENUE
OF COMPANIES
• Annual Reports
• Company Websites
• Public Databases
QUALITATIVE INFORMATION
(Market Dynamics and Trends)
• Company Websites
• Annual Reports
• Press Releases
• MarketsandMarkets Data Repository
• The following non-exclusive list of secondary sources was referred to:
• Associations/Organizations/Institutes:
• Organisation for Economic Co-operation and Development (OECD) Publications, European Association of
Nuclear Medicine (EANM), European Board of Nuclear Medicine (EBNM), National Institutes of Health (NIH),
World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission
(NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Board of
Radiation and Isotope Technology (BRIT), Nuclear Medicine Associations, Cancer Research UK, British Nuclear
Medicine Society (BNMS), Spanish Society of Nuclear Medicine (SEMN), Italian Association of Nuclear Medicine
& Molecular Imaging, and French Society of Nuclear Medicine.
• Background Study
• To build a basic understanding of diagnostic and therapeutic areas of nuclear medicine
• MarketsandMarkets data repository analysis, followed by drawing and updating data tables by using
current information
• Identifying data gaps and key players in each segment
•

• Market Understanding
• Identifying stakeholders and key decision makers in different countries
• Selection criteria of key decision makers
• Analyzing the competitive landscape
• Major players with their product portfolios
• Strategies adopted by the players to position their products
• Country-wise market analysis
• Trends
• Identifying and analyzing key products and trends to draw notes and include the consideration in the final
forecasts
• Major drivers, restraints, challenges, and opportunities prevailing in the market
2.2.2 PRIMARY RESEARCH
• Industry experts such as CEOs, presidents, vice presidents, directors, marketing directors, marketing managers,
and related key executives from various key companies and organizations in the nuclear medicine industry were
interviewed to obtain and verify both qualitative and quantitative aspects of this research study.
• A robust primary research methodology has been adopted to validate the contents of the report and to fill
in the gaps
• A telephonic and e-mail communication mode was adopted to conduct interviews (questionnaires were
designed and sent to primary participants as per their convenience)

2.2.3 KEY INDUSTRY INSIGHTS
•
Radiochemist, Leading
Nuclear Medicine Company
COO, Leading Nuclear
Medicine Company
Professor, Leading University Vice President, Leading
Nuclear Medicine Company
Russia keen to increase
its supply of Tc-99m
worldwide
“
“ Entry of Ra-223
radiopharmaceutical in the market
is likely to change the dynamics
of the European nuclear
medicine market.
“ “
Mallinckrodt (Ireland)
and GE Healthcare (U.K.) are
among the major players
of the European nuclear
medicine market.
“ “Alpha emitters is the
fastest-growing segment
of the therapeutics market.“
“
• FIGURE 4 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND
REGION
• BY COMPANY TYPE BY DESIGNATION BY COUNTRY
27%
43%
30%
Tier 1 Companies Tier 2 Companies
Tier 3 Companies
30%
33%
37%
C-level Director-level *Others
27%
17%
13%
23%
3%
7%
10%
Germany France Italy U.K.
Spain Russia RoE
• Note: *Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Company categorization according to revenue: Tier 1 (revenue more than USD 500 million), Tier 2 (revenue: USD 100 million to USD 500 million), and Tier 3 (revenue: Less than USD 100
million).

2.3 KEY DATA FROM PRIMARY SOURCES
• DATAPARAMETERSTYPE
 European nuclear medicine market, by country –
Germany, France, Italy, U.K., Spain, Russia, and
Rest of Europe (RoE)
 Overall market and
subsegments in 2014
 CAGR of each country in the
forecast period (2015–2020)
COUNTRY SPLIT
 European nuclear medicine market
 European nuclear medicine market, by type
 European nuclear medicine market,
by application
 The European nuclear medicine
market size for 2014
 CAGR for the forecast period
(2015–2020)
EUROPEAN
MARKET SIZE
 European nuclear medicine diagnostic market,
by type
 European nuclear medicine therapeutic market,
by type
 European nuclear medicine SPECT market,
by application
 European nuclear medicine PET market,
by application
 European nuclear medicine therapeutic market,
by application
 Diagnostic and therapeutic
markets
MARKET
SPLIT

2.4 KEY INSIGHTS FROM PRIMARY SOURCES
•
PARAMETER INSIGHT
EUROPEAN NUCLEAR MEDICINE MARKET
 The European nuclear medicine/radiopharmaceuticals market is estimated
to be valued at ~USD 1 billion in 2015
 The therapeutic segment is likely to grow at a higher CAGR as compared to
the diagnostics segment
EUROPEAN NUCLEAR MEDICINE MARKET,
BY COUNTRY
 Germany is estimated to account for the largest share of ~25% of the
European nuclear medicine market in 2015, and is expected to grow at a
CAGR of ~9% from 2015 to 2020
 Growth in this market can be attributed to a new irradiation facility in
Germany and research programs conducted in Germany
 Rest of Europe (RoE) will register the highest CAGR of ~14% in the
European nuclear medicine market
 U.K. is expected to account for a share of ~15% in the European nuclear
medicine market in 2015
 The European nuclear medicine market is expected to grow at a CAGR of
~8% owing to the EC approval for alpha emitters in Europe, increasing
awareness of radioisotope therapy in the U.K., Russia is seen as an
upcoming country for radionuclide therapy, and increasing acceptability of
18F-FDG PET-CT in the U.K., among other factors
DRIVERS AND CHALLENGES OF THE
MARKET
 According to primary sources, rising aging and chronically ill population and
alpha radio immunotherapy-based targeted cancer treatment are the major
drivers for the European nuclear medicine market
 Shorter half-life of radiopharmaceuticals and competition from conventional
diagnostic procedures are likely to restrain the growth of the European
nuclear medicine market
2.5 MARKET SIZE ESTIMATION METHODOLOGY
• Both, top-down and bottom-up approaches were used to estimate and validate the size of the European market
and to estimate the size of various other dependent submarkets in the overall European nuclear medicine/
radiopharmaceuticals market. The research methodology used to estimate the market size includes the following
details:
• The key players in the market were identified through secondary research and their market shares were determined
through primary and secondary research. This entire procedure includes the study of the annual and financial
reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs,
VPs, directors, and marketing executives. All percentage shares, splits, and breakdowns were determined by
using secondary sources and verified through primary sources. All possible parameters that affect the markets
covered in this research study have been accounted for, viewed in extensive detail, verified through primary
research, and analyzed to get the final quantitative and qualitative data. This data is consolidated and added with
detailed inputs and analysis from MarketsandMarkets and presented in this report.
• The following figure shows an illustrative representation of the overall market size estimation process employed
for the purpose of this study.
•

• FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
• Size Estimation of the European Nuclear
Medicine/Radiopharmaceuticals Market
(Value Analysis)
PRIMARY RESEARCH: Industry Experts/Key Opinion
Leaders (KOLs)/Subject-matter Experts (SMEs) from
Demand and Supply Sides
SECONDARY RESEARCH: Annual Reports, SEC Filings,
Organisation for Economic Co-operation and
Development (OECD) Publications, European Association of
Nuclear Medicine (EANM), European Board of Nuclear
Medicine (EBNM), National Institutes of Health (NIH), World
Nuclear Association (WNA), International Atomic Energy
Agency (IAEA), Nuclear Regulatory Commission (NRC),
Society of Nuclear Medicine and Molecular Imaging (SNMMI),
Nuclear Energy Agency (NEA), Board of Radiation and Isotope
Technology (BRIT), Nuclear Medicine Associations, Cancer
Research UK, British Nuclear Medicine Society (BNMS),
Spanish Society of Nuclear Medicine (SEMN), Italian
Association of Nuclear Medicine & Molecular Imaging, French
Society of Nuclear Medicine, Experts Interviews, and
MarketsandMarkets Analysis
A
Calculation
of the
market* to 100%
to arrive at the
European nuclear
medicine
market
Mapping the revenues,
by company, to the extent
of ~45% of the market covered
Mapping the revenues generated by
sales of nuclear medicines/radiopharmaceuticals in
Europe, by company
Generating the list of players operating in different segments and
subsegments of the European nuclear medicine/radiopharmaceuticals
market
• Note: *The market numbers were validated by key players operating in the market.
Note: A refers to the total market size for the European Nuclear Medicine/ Radiopharmaceuticals Market (in terms of value)
• FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY:TOP-DOWN APPROACH
•
Size Estimation of the European Nuclear
Medicine/Radiopharmaceuticals Market
(Value Analysis)
PRIMARY RESEARCH: Industry Experts/Key Opinion Leaders
(KOLs)/Subject-matter Experts (SMEs) from Demand and Supply Sides
SECONDARY RESEARCH: Annual Reports, SEC Filings, Organisation for
Economic Co-operation and Development (OECD) Publications, European
Association of Nuclear Medicine (EANM), European Board of Nuclear
Medicine (EBNM), National Institutes of Health (NIH), World Nuclear
Association (WNA), International Atomic Energy Agency (IAEA), Nuclear
Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular
Imaging (SNMMI), Nuclear Energy Agency (NEA), Board of Radiation and
Isotope Technology (BRIT), Nuclear Medicine Associations, Cancer Research
UK, British Nuclear Medicine Society (BNMS), Spanish Society of Nuclear
Medicine (SEMN), Italian Association of Nuclear Medicine & Molecular
Imaging, French Society of Nuclear Medicine, Experts Interviews, and
MarketsandMarkets Analysis
AMarket Size of Segments and Regions,
by Value
Percentage Split of the European
Nuclear Medicine Market, by
Segment (Type, Application, and
Country)
European Nuclear
Medicine
Market
• Note: A refers to the total market size for the European nuclear medicine/radiopharmaceuticals market (in terms of value).

2.6 RESEARCH DESIGN
• FIGURE 7 RESEARCH DESIGN
•
MARKET DRIVERS:
• Increasing preference for
SPECT and PET scans
• Advances in radiotracers
• Alpha radio
immunotherapy-based
targeted cancer treatment
• Increasing incidence and
mortality rate of cancer
and cardiac ailments
MARKET
RESTRAINTS:
• Shorter half-life of
radiopharmaceuticals
• Competition from
conventional diagnostic
procedures
MARKET
OPPORTUNITIES:
• Potential radioisotopes in
the pipeline
• Cyclotron based
production
• GEOGRAPHICAL ANALYSIS: Market Dynamics and Business Environment in
Germany, France, Italy, U.K., Spain, Russia, and Rest of Europe (RoE)
HISTORICAL DATA
FOR THE NUCLEAR
MEDICINE
MARKET
INFLUENCING
FACTORS
(Market Trends and
Dynamics)
HISTORICAL DATA OF
THE MARKET
MARKET SIZE &
FORECAST:
• By Type
• By Application
• By Country
ARRIVE AT THE
MARKET SIZE, SHARE,
AND CAGR FOR THE
EUROPEAN NUCLEAR
MEDICINE/RADIOPHAR
MACEUTICALS
MARKET
GEOGRAPHICAL USAGE
PATTERN AND
TECHNOLOGY TRENDS
PIPELINE
ASSESSMENT
MARKET SHARE
COMPETITIVE
LANDSCAPE
COMPANY REVENUES &
R&D EXPENSES
IMPACT ANALYSIS OF
MARKET TRENDS
FORECAST
• AGREEMENTS AND CONTRACTS: About 9 deals
in the last three years
• ACQUISITIONS: About 4 deals in the last three
years
PROCEDURAL VOLUME

2.7 MARKET DATA VALIDATION AND TRIANGULATION
• In order to complete the overall market engineering process and to arrive at the exact statistics for all the market
segments and sub-segments, data triangulation and market validation procedures explained below were
implemented, wherever applicable.
• FIGURE 8 DATA TRIANGULATION METHODOLOGY
•
MnM KNOW* stands for ‘MarketsandMarkets Knowledge Asset Management' framework. In this context, it stands for the existing market
research knowledge repository of over 5,000 granular markets, our flagship competitive intelligence and market research platform "RT",
subject-matter experts, and independent consultants. MnM KNOW acts as an independent source that helps us validate information
gathered from primary and secondary sources.
SECONDARY SOURCESPRIMARY SOURCES
Annual Reports, Presentations, Websites
and Press Releases
of Top Players, News Articles,
Journals, and Paid Databases
INTERVIEWS WITH:
• Surgeons and Physicians
• Endocrinologists,
Nephrologists, Cardiologists,
and Rheumatologists
• Radiologists and
Radiochemists
DEMANDSIDE
INTERVIEWS WITH:
• Presidents, CEOs, Vice
Presidents, Directors,
General Managers, and
Senior Managers
• Product/Sales/Marketing/Busi
ness Development/Client
Portfolio Managers or
Specialists,
Distributors/Suppliers/Chann
el Partners, Business
Intelligence Consultants, and
Radiochemists
SUPPLYSIDE
INFORMATION SOURCED
Key Players Competitive Landscape
Opportunities and
Challenges
Market Size and Market
Share (2015)
MnM KNOW*
PRIMARY
SOURCES
SECONDARY
SOURCES
DATA
TRIANGULATION
SECONDARY RESEARCH: Annual Reports, SEC
Filings, Organisation for Economic Co-operation
and Development (OECD) Publications, European
Association of Nuclear Medicine (EANM),
European Board of Nuclear Medicine (EBNM),
National Institutes of Health (NIH), World Nuclear
Association (WNA), International Atomic Energy
Agency (IAEA), Nuclear Regulatory
Commission (NRC), Society of Nuclear Medicine
and Molecular Imaging (SNMMI), Nuclear Energy
Agency (NEA), Board of Radiation and Isotope
Technology (BRIT), Nuclear Medicine
Associations, Cancer Research UK, British
Nuclear Medicine Society (BNMS), Spanish
Society of Nuclear Medicine (SEMN), Italian
Association of Nuclear Medicine & Molecular
Imaging, French Society of Nuclear Medicine,
Experts Interviews, and MarketsandMarkets
Analysis
Drivers and Restraints Forecast Pipeline Assessment Geographical Analysis
Procedural Volume
• MnM KNOW* stands for ‘MarketsandMarkets Knowledge Asset Management’ framework. In this context, it stands for the existing market research knowledge repository of over 5,000 granular
markets, our flagship competitive intelligence and market research platform “RT”, subject-matter experts, and independent consultants. MnM KNOW acts as an independent source that helps us
validate information gathered from primary and secondary sources.
2.8 ASSUMPTIONS FOR THE STUDY
• PARAMETER ASSUMPTION
GENERAL ASSUMPTIONS
• There will be no drastic changes in the market scenario during the
forecast period
• There will be no changes in regulations that have a huge impact
on the industry

1 INTRODUCTION.........................................................................................................................17
• 1.1 OBJECTIVES OF STUDY...................................................................................................................................................20
• 1.2 MARKET DEFINITION.......................................................................................................................................................20
• 1.3 MARKET SCOPE...............................................................................................................................................................21
• 1.3.1 MARKETS COVERED......................................................................................................................................21
• 1.3.2 YEARS CONSIDERED FOR THE STUDY.........................................................................................................22
• 1.4 CURRENCY......................................................................................................................................................................22
• 1.5 LIMITATIONS....................................................................................................................................................................22
• 1.6 STAKEHOLDERS...............................................................................................................................................................22
2 RESEARCH METHODOLOGY.....................................................................................................23
• 2.1 RESEARCH METHODOLOGY STEPS................................................................................................................................23
• 2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY.............................................................................................24
• 2.2.1 SECONDARY RESEARCH...............................................................................................................................24
• 2.2.2 PRIMARY RESEARCH....................................................................................................................................25
• 2.2.3 KEY INDUSTRY INSIGHTS.............................................................................................................................25
• 2.3 KEY DATA FROM PRIMARY SOURCES............................................................................................................................26
• 2.4 KEY INSIGHTS FROM PRIMARY SOURCES.....................................................................................................................27
• 2.5 MARKET SIZE ESTIMATION METHODOLOGY..................................................................................................................27
• 2.6 RESEARCH DESIGN.........................................................................................................................................................29
• 2.7 MARKET DATA VALIDATION AND TRIANGULATION........................................................................................................30
• 2.8 ASSUMPTIONS FOR THE STUDY....................................................................................................................................30
3 EXECUTIVE SUMMARY..............................................................................................................31
• 3.1 INTRODUCTION...............................................................................................................................................................31
• 3.2 CURRENT SCENARIO.......................................................................................................................................................32
• 3.3 FUTURE OUTLOOK...........................................................................................................................................................32
4 PREMIUM INSIGHTS.................................................................................................................35
• 4.1 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET.......................................................................35
• 4.2 SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET, BY COUNTRY AND APPLICATION..36
• 4.3 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY COUNTRY................................................37
• 4.4 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE (2015 VS. 2020).............................38
TABLE OF CONTENTS

5 MARKET OVERVIEW..................................................................................................................39
• 5.1 INTRODUCTION...............................................................................................................................................................40
• 5.2 MARKET DYNAMICS........................................................................................................................................................40
• 5.2.1 DRIVERS........................................................................................................................................................40
• 5.2.1.1 INCREASING PREFERENCE FOR SPECT AND PET SCANS......................................................40
• 5.2.1.2 ADVANCES IN RADIOTRACERS................................................................................................41
• 5.2.1.3 ALPHA RADIOIMMUNOTHERAPY-BASED TARGETED CANCER TREATMENT..........................41
• 5.2.1.4 GROWING INCIDENCE RATE OF CANCER AND CARDIAC AILMENTS.....................................42
• 5.2.2 RESTRAINTS..................................................................................................................................................43
• 5.2.2.1 SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS.............................................................43
• 5.2.2.2 COMPETITION FROM CONVENTIONAL DIAGNOSTIC PROCEDURES......................................43
• 5.2.3 OPPORTUNITIES............................................................................................................................................43
• 5.2.3.1 POTENTIAL RADIOISOTOPES IN THE PIPELINE.......................................................................43
• 5.2.3.2 CYCLOTRON-BASED PRODUCTION........................................................................................44
• 5.2.4 CHALLENGE...................................................................................................................................................45
• 5.2.4.1 SHUTDOWN OF NUCLEAR REACTORS....................................................................................45
• 5.2.5 BURNING ISSUE............................................................................................................................................45
• 5.2.5.1 LOW HEALTHCARE SPENDING IN EUROPE..............................................................................45
• 5.3 REGULATORY SCENARIO.................................................................................................................................................46
• 5.3.1 INTRODUCTION.............................................................................................................................................46
• 5.3.2 GERMANY......................................................................................................................................................46
• 5.3.2.1 GERMAN MEDICINAL PRODUCTS ACT (AMG)........................................................................46
• 5.3.2.2 AMENDMENTS TO THE GERMAN MEDICINAL PRODUCTS ACT (AMG).................................46
• 5.3.3 FRANCE.........................................................................................................................................................47
• 5.3.3.1 AGENCE NATIONALE DE SÉCURITÉ DU MÉDICAMENT ET DES PRODUITS
DE SANTÉ (ANSM)...................................................................................................................47
• 5.3.4 U.K.................................................................................................................................................................47
• 5.3.4.1 THE MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA)................47
• 5.3.5 SPAIN.............................................................................................................................................................47
• 5.3.6 ITALY..............................................................................................................................................................48
• 5.3.6.1 THE ITALIAN PHARMACEUTICAL AGENCY (AIFA)...................................................................48
TABLE OF CONTENTS

• 5.3.7 RUSSIA..........................................................................................................................................................48
• 5.3.7.1 THE FEDERAL LAW...................................................................................................................48
• 5.3.8 SWITZERLAND...............................................................................................................................................48
• 5.3.8.1 FEDERAL DEPARTMENT OF HOME AFFAIRS (FDHA)- THE ULTIMATE DECISION MAKER......48
• 5.3.8.2 THE SWISS AGENCY FOR THERAPEUTIC PRODUCTS (SATP)................................................49
6 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, PIPELINE
ASSESSMENT............................................................................................................................50
• 6.1 INTRODUCTION...............................................................................................................................................................51
• 6.2 DIAGNOSTIC RADIOISOTOPES........................................................................................................................................53
• 6.2.1 F-18...............................................................................................................................................................55
• 6.3 THERAPEUTIC RADIOISOTOPES......................................................................................................................................57
• 6.3.1 RA-223...........................................................................................................................................................59
• 6.3.2 LU-177...........................................................................................................................................................61
7 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE...................63
• 7.1 INTRODUCTION...............................................................................................................................................................64
• 7.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS....................................................................................65
• 7.2.1 SPECT RADIOPHARMACEUTICALS...............................................................................................................67
• 7.2.1.1 TECHNETIUM-99M...................................................................................................................68
• 7.2.1.2 THALLIUM-201.........................................................................................................................69
• 7.2.1.3 GALLIUM-67.............................................................................................................................70
• 7.2.1.4 IODINE-123...............................................................................................................................71
• 7.2.1.5 OTHERS....................................................................................................................................72
• 7.2.2 PET RADIOPHARMACEUTICALS...................................................................................................................73
• 7.2.2.1 FLUORINE-18...........................................................................................................................74
• 7.2.2.2 RUBIDIUM-82...........................................................................................................................75
• 7.2.2.3 OTHERS....................................................................................................................................76
• 7.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS.................................................................................77
• 7.3.1 BETA EMITTERS.............................................................................................................................................79
• 7.3.1.1 IODINE-131...............................................................................................................................80
• 7.3.1.2 YTTRIUM-90.............................................................................................................................81
TABLE OF CONTENTS

• 7.3.1.3 SAMARIUM-153.......................................................................................................................82
• 7.3.1.4 RHENIUM-186..........................................................................................................................83
• 7.3.1.5 LUTETIUM-177.........................................................................................................................84
• 7.3.1.6 OTHERS....................................................................................................................................84
• 7.3.2 ALPHA EMITTERS..........................................................................................................................................85
• 7.3.2.1 RADIUM-223............................................................................................................................86
• 7.3.3 BRACHYTHERAPY.........................................................................................................................................86
• 7.3.3.1 IODINE-125...............................................................................................................................88
• 7.3.3.2 IRIDIUM-192.............................................................................................................................89
• 7.3.3.3 PALLADIUM-103......................................................................................................................89
• 7.3.3.4 CESIUM-131.............................................................................................................................90
• 7.3.3.5 OTHERS....................................................................................................................................91
8 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET,
BY APPLICATION.......................................................................................................................92
• 8.1 INTRODUCTION...............................................................................................................................................................93
• 8.2 DIAGNOSTIC APPLICATIONS...........................................................................................................................................93
• 8.2.1 SPECT APPLICATIONS..................................................................................................................................93
• 8.2.1.1 CARDIOLOGY...........................................................................................................................96
• 8.2.1.2 LYMPHOMA..............................................................................................................................97
• 8.2.1.3 NEUROLOGY.............................................................................................................................98
• 8.2.1.4 THYROID...................................................................................................................................99
• 8.2.1.5 OTHER SPECT APPLICATIONS...............................................................................................100
• 8.2.2 PET APPLICATIONS.....................................................................................................................................101
• 8.2.2.1 ONCOLOGY............................................................................................................................104
• 8.2.2.2 CARDIOLOGY.........................................................................................................................104
• 8.2.2.3 NEUROLOGY...........................................................................................................................105
• 8.2.2.4 OTHER PET APPLICATIONS....................................................................................................106
• 8.3 THERAPEUTIC APPLICATIONS......................................................................................................................................107
• 8.3.1 THYROID......................................................................................................................................................110
• 8.3.2 BONE METASTASIS......................................................................................................................................111
• 8.3.3 LYMPHOMA.................................................................................................................................................112
TABLE OF CONTENTS

• 8.3.4 ENDOCRINE TUMORS.................................................................................................................................113
• 8.3.5 OTHER THERAPEUTIC APPLICATIONS........................................................................................................114
9 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS, PROCEDURAL VOLUME.......116
• 9.1 INTRODUCTION.............................................................................................................................................................117
• 9.2 EUROPEAN DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME.......................118
• 9.2.1 SPECT RADIOPHARMACEUTICALS.............................................................................................................118
• 9.2.2 PET RADIOPHARMACEUTICALS.................................................................................................................119
• 9.3 EUROPEAN THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME.....................119
• 9.3.1 BETA EMITTERS...........................................................................................................................................120
• 9.3.2 ALPHA EMITTERS........................................................................................................................................120
• 9.3.3 BRACHYTHERAPY.......................................................................................................................................121
10 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET,
BY COUNTRY/REGION.............................................................................................................122
• 10.1 INTRODUCTION.............................................................................................................................................................123
• 10.2 GERMANY......................................................................................................................................................................126
• 10.3 FRANCE..........................................................................................................................................................................131
• 10.4 ITALY..............................................................................................................................................................................136
• 10.5 U.K.................................................................................................................................................................................141
• 10.6 SPAIN.............................................................................................................................................................................146
• 10.7 RUSSIA...........................................................................................................................................................................151
• 10.8 REST OF EUROPE (ROE)................................................................................................................................................156
11 COMPETITIVE LANDSCAPE.....................................................................................................162
• 11.1 OVERVIEW......................................................................................................................................................................162
• 11.2 COMPETITIVE SITUATION AND TRENDS.......................................................................................................................162
• 11.2.1 INTRODUCTION...........................................................................................................................................162
• 11.2.2 AGREEMENTS CONTRACTS....................................................................................................................163
• 11.2.3 ACQUISITIONS.............................................................................................................................................164
• 11.2.4 MARKET DEVELOPMENTS..........................................................................................................................164
• 11.2.5 EXPANSIONS...............................................................................................................................................165
• 11.2.6 OTHER STRATEGIES....................................................................................................................................165
TABLE OF CONTENTS

12 COMPANY PROFILES...............................................................................................................166
• (Overview, Financials, Products Services, Strategy, and Developments)*
• 12.1 CARDINAL HEALTH, INC................................................................................................................................................166
• 12.2 MALLINCKRODT PLC....................................................................................................................................................168
• 12.3 GE HEALTHCARE............................................................................................................................................................170
• 12.4 LANTHEUS MEDICAL IMAGING, INC.............................................................................................................................172
• 12.5 BAYER HEALTHCARE.....................................................................................................................................................174
• 12.6 BRACCO IMAGING S.P.A................................................................................................................................................176
• 12.7 ECZACIBASI-MONROL NUCLEAR PRODUCTS..............................................................................................................178
• 12.8 NORDION, INC...............................................................................................................................................................180
• 12.9 ADVANCED ACCELERATOR APPLICATIONS S.A...........................................................................................................182
• 12.10 IBA MOLECULAR IMAGING...........................................................................................................................................184
• *Details on overview, financials, product services, strategy, and developments might not be captured in case of unlisted companies.
13 APPENDIX................................................................................................................................186
• 13.1 DISCUSSION GUIDE......................................................................................................................................................186
• 13.2 AVAILABLE CUSTOMIZATIONS......................................................................................................................................194
• 13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE..............................................................................................194
• 13.4 RELATED REPORTS........................................................................................................................................................195
•
TABLE OF CONTENTS

• TABLE 1 ALPHA RADIO IMMUNOTHERAPY-BASED TARGETED CANCER TREATMENT TO BOOST
THE GROWTH OF THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET.....................42
• TABLE 2 SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS RESTRAINING THE GROWTH OF
THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET..................................................43
• TABLE 3 POTENTIAL RADIOISOTOPES IN THE PIPELINE OFFER SIGNIFICANT GROWTH OPPORTUNITIES
FOR THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET..........................................44
• TABLE 4 SHUTDOWN OF NUCLEAR REACTORS IS A MAJOR CHALLENGE IN THE EUROPEAN
NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET.............................................................................45
• TABLE 5 LOW HEALTHCARE SPENDING IN EUROPE IS A MAJOR BURNING ISSUE IN THE EUROPEAN
NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET.............................................................................46
• TABLE 6 DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING DIAGNOSTIC APPLICATIONS...............................54
• TABLE 7 DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING THERAPEUTIC APPLICATIONS.............................58
• TABLE 8 EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY TYPE, 2013-2020 (USD MILLION)...............................................................................................................65
• TABLE 9 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS
MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)...............................................................................66
• TABLE 10 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
• TABLE 11 EUROPE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY COUNTRY, 2013-2020 (USD MILLION)........................................................................................................68
• TABLE 12 EUROPE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY ISOTOPE TYPE, 2013-2020 (USD MILLION)................................................................................................68
• TABLE 13 EUROPE: TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)................................69
• TABLE 14 EUROPE: THALLIUM-201 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)......................................70
• TABLE 15 EUROPE: GALLIUM-67 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)..........................................71
• TABLE 16 EUROPE: IODINE-123 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)............................................72
• TABLE 17 EUROPE: OTHER SPECT ISOTOPES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)......................73
• TABLE 18 EUROPE: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
• TABLE 19 EUROPE: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY ISOTOPE TYPE, 2013-2020 (USD MILLION)................................................................................................74
• TABLE 20 EUROPE: FLUORINE-18 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION).........................................75
• TABLE 21 EUROPE: RUBIDIUM-82 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)........................................76
LIST OF TABLES

• TABLE 22 EUROPE: OTHER PET ISOTOPES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)...........................77
• TABLE 23 EUROPE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
SIZE, BY COUNTRY, 2013-2020 (USD MILLION)...............................................................................................78
• TABLE 24 EUROPE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
• TABLE 25 EUROPE: BETA EMITTERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION).....................................80
• TABLE 26 EUROPE: BETA EMITTERS MARKET SIZE, BY ISOTOPE TYPE, 2013-2020 (USD MILLION).............................80
• TABLE 28 EUROPE: YTTRIUM-90 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)..........................................82
• TABLE 29 EUROPE: SAMARIUM-153 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION).....................................83
• TABLE 30 EUROPE: RHENIUM-186 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)........................................83
• TABLE 31 EUROPE: LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)......................................84
• TABLE 32 EUROPE: OTHER BETA EMITTER ISOTOPES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION).........85
• TABLE 33 EUROPE: ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)..................................86
• TABLE 34 EUROPE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)................87
• TABLE 35 EUROPE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2013-2020 (USD MILLION)........88
• TABLE 37 EUROPE: IRIDIUM-192 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)..........................................89
• TABLE 38 EUROPE: PALLADIUM-103 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)....................................90
• TABLE 39 EUROPE: CESIUM-131 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)..........................................90
• TABLE 40 EUROPE: OTHER BRACHYTHERAPY ISOTOPES MARKET SIZE,
• TABLE 41 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS,
• TABLE 42 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS,
• TABLE 43 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY
SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION).................................................................97
• TABLE 44 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA
• TABLE 45 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY
LIST OF TABLES

• TABLE 46 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID SPECT
APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)...........................................................................100
• TABLE 47 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER SPECT
• TABLE 48 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS,
BY COUNTRY, 2013-2020 (USD MILLION)......................................................................................................102
• TABLE 49 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS,
BY TYPE, 2013-2020 (USD MILLION).............................................................................................................103
• TABLE 50 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ONCOLOGY PET
• TABLE 51 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY PET
• TABLE 52 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY PET
• TABLE 53 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER PET
• TABLE 54 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC
• TABLE 55 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC
APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)...................................................................................109
• TABLE 56 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID THERAPEUTIC
• TABLE 57 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BONE METASTASIS
THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)...................................................112
• TABLE 58 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA THERAPEUTIC
• TABLE 59 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ENDOCRINE THERAPEUTIC
• TABLE 60 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER
THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)...................................................115
• TABLE 61 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME,
BY TYPE, 2013–2020 (THOUSAND)................................................................................................................117
• TABLE 62 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME,
BY COUNTRY, 2013–2020 (THOUSAND).........................................................................................................117
• TABLE 63 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC PROCEDURAL
VOLUME, BY TYPE, 2013–2020 (THOUSAND)................................................................................................118
LIST OF TABLES

• TABLE 64 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR SPECT
RADIOPHARMACEUTICALS, BY TYPE, 2013–2020 (THOUSAND)..................................................................118
• TABLE 65 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR PET
RADIOPHARMACEUTICALS, BY TYPE, 2013–2020 (THOUSAND)..................................................................119
• TABLE 66 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC PROCEDURAL
VOLUME, BY TYPE, 2013–2020 (THOUSAND)................................................................................................119
• TABLE 67 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR BETA EMITTERS,
BY TYPE, 2013–2020 (THOUSAND)...............................................................................................................120
• TABLE 68 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR ALPHA EMITTERS,
BY TYPE, 2013–2020 (THOUSAND)...............................................................................................................120
• TABLE 69 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR BRACHYTHERAPY,
BY TYPE, 2013–2020 (THOUSAND)...............................................................................................................121
• TABLE 70 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY COUNTRY, 2013–2020 (USD MILLION).....................................................................................................124
• TABLE 71 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY TYPE, 2013–2020 (USD MILLION).............................................................................................................126
• TABLE 72 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE,
• TABLE 73 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,
• TABLE 74 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,
• TABLE 75 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,
• TABLE 76 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA
EMITTERS, BY TYPE, 2013–2020 (USD MILLION)..........................................................................................129
• TABLE 77 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR
BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION)..............................................................................129
• TABLE 78 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,
BY APPLICATION, 2013–2020 (USD MILLION)...............................................................................................130
• TABLE 79 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,
• TABLE 80 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,
• TABLE 81 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY TYPE, 2013–2020 (USD MILLION)............................................................................................................132
LIST OF TABLES

• TABLE 82 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE,
• TABLE 83 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,
• TABLE 84 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,
• TABLE 85 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,
• TABLE 86 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS,
• TABLE 87 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY,
• TABLE 88 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,
• TABLE 89 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,
• TABLE 90 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,
• TABLE 91 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
• TABLE 92 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE,
• TABLE 93 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,
• TABLE 94 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,
• TABLE 95 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,
• TABLE 96 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS,
• TABLE 97 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY,
• TABLE 98 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,
• TABLE 99 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,
LIST OF TABLES

• TABLE 100 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,
• TABLE 101 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE,
2013–2020 (USD MILLION).............................................................................................................................142
• TABLE 102 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE,
• TABLE 103 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,
• TABLE 104 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,
• TABLE 105 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,
• TABLE 106 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS,
• TABLE 107 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY,
• TABLE 108 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,
• TABLE 109 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,
• TABLE 110 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,
• TABLE 111 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE,
2013–2020 (USD MILLION).............................................................................................................................147
• TABLE 112 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE,
• TABLE 113 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,
• TABLE 114 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,
• TABLE 115 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,
• TABLE 116 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS,
LIST OF TABLES

• TABLE 117 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR
• TABLE 118 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,
• TABLE 119 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,
• TABLE 120 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,
• TABLE 121 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY TYPE, 2013–2020 (USD MILLION)............................................................................................................152
• TABLE 122 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE,
• TABLE 123 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,
• TABLE 124 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,
• TABLE 125 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,
• TABLE 126 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA
EMITTERS, BY TYPE, 2013–2020 (USD MILLION)..........................................................................................154
• TABLE 127 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR
• TABLE 128 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,
• TABLE 129 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,
• TABLE 130 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,
• TABLE 131 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE,
2013–2020 (USD MILLION).............................................................................................................................157
• TABLE 132 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE,
• TABLE 133 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,
LIST OF TABLES

• TABLE 134 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,
• TABLE 135 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,
• TABLE 136 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS,
• TABLE 137 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY,
• TABLE 138 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,
• TABLE 139 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,
• TABLE 140 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,
• TABLE 141 AGREEMENTS CONTRACTS, 2012-2015.....................................................................................................163
• TABLE 142 ACQUISITIONS, 2012-2015.............................................................................................................................164
• TABLE 143 MARKET DEVELOPMENTS, 2012-2015...........................................................................................................164
• TABLE 144 EXPANSIONS, 2012-2015................................................................................................................................165
• TABLE 145 OTHER STRATEGIES, 2012-2015.....................................................................................................................165
•
LIST OF TABLES

• FIGURE 1 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICAL MARKET SEGMENTATION................................21
• FIGURE 2 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: RESEARCH
METHODOLOGY STEPS.....................................................................................................................................23
• FIGURE 3 KEY DATA FROM SECONDARY SOURCES.........................................................................................................24
• FIGURE 4 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION......................26
• FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH.........................................................28
• FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH...........................................................28
• FIGURE 7 RESEARCH DESIGN...........................................................................................................................................29
• FIGURE 8 DATA TRIANGULATION METHODOLOGY...........................................................................................................30
• FIGURE 9 THERAPEUTIC MARKET TO WITNESS HIGH GROWTH RATE FROM 2015 TO 2020..........................................31
• FIGURE 10 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SHARE,
BY TYPE, 2015 VS. 2020...................................................................................................................................32
• FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS
MARKET, 2015...................................................................................................................................................33
• FIGURE 12 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS SPECT APPLICATIONS
MARKET SIZE, 2015 VS. 2020...........................................................................................................................34
• FIGURE 13 ADVANCES IN RADIOTRACERS TO PROPEL MARKET GROWTH......................................................................35
• FIGURE 14 GERMANY DOMINATES THE EUROPEAN SPECT NUCLEAR MEDICINE DIAGNOSTIC MARKET IN 2015.........36
• FIGURE 15 REST OF EUROPE TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD..................................37
• FIGURE 16 DIAGNOSTIC SEGMENT TO COMMAND THE LARGEST MARKET SHARE DURING
THE FORECAST PERIOD....................................................................................................................................38
• FIGURE 17 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, CHALLENGES....................................................................................................................40
• FIGURE 18 CLINICAL TRIALS STUDIES OF RADIOISOTOPES, BY COUNTRY.....................................................................51
• FIGURE 19 CLINICAL TRIALS FOR DIAGNOSTIC THERAPEUTIC RADIOISOTOPES, BY PHASE......................................52
• FIGURE 20 CLINICAL TRIALS FOR DIAGNOSTIC THERAPEUTIC RADIOISOTOPES, BY COMPANY INSTITUTE........52
• FIGURE 21 CLINICAL TRIALS FOR RADIOISOTOPES, BY TYPE..........................................................................................53
• FIGURE 22 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY SUBTYPE.............................................................53
• FIGURE 23 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY INDICATION.........................................................54
• FIGURE 24 CLINICAL TRIALS FOR F-18, BY COUNTRY......................................................................................................55
• FIGURE 25 CLINICAL TRIALS FOR F-18, BY PHASE...........................................................................................................55
• FIGURE 26 CLINICAL TRIALS FOR F-18, BY INDICATION...................................................................................................56
• FIGURE 27 CLINICAL TRIALS FOR F-18, BY COMPANY/INSTITUTE...................................................................................56
LIST OF FIGURES

• FIGURE 28 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY SUBTYPE...........................................................57
• FIGURE 29 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY INDICATION.......................................................58
• FIGURE 30 CLINICAL TRIALS FOR RA-223, BY COUNTRY..................................................................................................59
• FIGURE 31 CLINICAL TRIALS FOR RA-223, BY PHASE.......................................................................................................59
• FIGURE 32 CLINICAL TRIALS FOR RA-223, BY INDICATION...............................................................................................60
• FIGURE 33 CLINICAL TRIALS FOR RA-223, BY COMPANY/INSTITUTE..............................................................................60
• FIGURE 34 CLINICAL TRIALS FOR LU-177, BY COUNTRY..................................................................................................61
• FIGURE 35 CLINICAL TRIALS FOR LU-177, BY PHASE.......................................................................................................61
• FIGURE 36 CLINICAL TRIALS FOR LU-177, BY INDICATION...............................................................................................61
• FIGURE 37 CLINICAL TRIALS FOR LU-177, BY COMPANY/INSTITUTE..............................................................................62
• FIGURE 38 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION, BY TYPE..............64
• FIGURE 39 THERAPEUTIC SEGMENT TO GROW AT A HIGHER CAGR OF 10.2%................................................................65
• FIGURE 40 PET SEGMENT TO GROW AT THE HIGHER CAGR OF 13.1% DURING THE FORECAST PERIOD......................67
• FIGURE 41 ALPHA EMITTERS SEGMENT TO GROW AT THE HIGHEST CAGR OF 12.7% DURING
• FIGURE 42 SEGMENTATION OF EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
FOR SPECT APPLICATIONS, BY TYPE...............................................................................................................94
• FIGURE 43 REST OF EUROPE REGION TO GROW AT THE HIGHEST CAGR OF 13.2% DURING
• FIGURE 44 NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 8.1% DURING
• FIGURE 45 SEGMENTATION OF EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS
MARKET FOR PET APPLICATIONS, BY TYPE..................................................................................................101
THE FORECAST PERIOD..................................................................................................................................102
• FIGURE 47 NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 16.4% DURING
• FIGURE 48 SEGMENTATION OF EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR
THERAPEUTIC APPLICATIONS, BY TYPE........................................................................................................108
• FIGURE 50 THE ENDOCRINE TUMORS APPLICATION SEGMENT TO GROW AT THE HIGHEST
CAGR OF 13.0% DURING THE FORECAST PERIOD........................................................................................110
LIST OF FIGURES

• FIGURE 51 GERMANY TO COMMAND THE LARGEST SHARE OF THE EUROPEAN NUCLEAR MEDICINE
MARKET FOR DIAGNOSTIC IN 2015................................................................................................................124
• FIGURE 52 THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET TO GROW AT A
CAGR OF 8.2% DURING THE FORECAST PERIOD..........................................................................................125
• FIGURE 53 BATTLE FOR MARKET SHARE: AGREEMENTS CONTRACTS WAS THE KEY STRATEGY ADOPTED
BY PLAYERS BETWEEN 2012 2015..............................................................................................................162
• FIGURE 54 CARDINAL HEALTH, INC.: COMPANY SNAPSHOT..........................................................................................166
• FIGURE 55 MALLINCKRODT PLC: COMPANY SNAPSHOT...............................................................................................168
• FIGURE 56 GE HEALTHCARE: COMPANY SNAPSHOT.......................................................................................................170
• FIGURE 57 LANTHEUS MEDICAL IMAGING, INC.: COMPANY SNAPSHOT......................................................................172
• FIGURE 58 BAYER HEALTHCARE: COMPANY SNAPSHOT................................................................................................174
• FIGURE 59 NORDION, INC.: COMPANY SNAPSHOT.........................................................................................................180
• FIGURE 60 ADVANCED ACCELERATOR APPLICATIONS S.A.: COMPANY SNAPSHOT.....................................................182
•
•
LIST OF FIGURES

TABLE 1 EUROPE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY ISOTOPE TYPE, 2013-2020 (USD MILLION)
ISOTOPE 2013 2014 2015-e 2020-p
CAGR
(2015-2020)
Tc-99 xx.x xx.x xx.x xx.x xx.x%
Tl-201 xx.x xx.x xx.x xx.x xx.x%
Ga-67 xx.x xx.x xx.x xx.x xx.x%
I-123 xx.x xx.x xx.x xx.x xx.x%
Others xx.x xx.x xx.x xx.x xx.x%
TOTAL xx.x xx.x xx.x xx.x xx.x%
Source: Organisation for Economic Co-operation and Development (OECD) Publications, European Association of Nuclear Medicine (EANM), European Board of Nuclear Medicine (EBNM), National Institutes
of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear
Energy Agency (NEA), Board of Radiation and Isotope Technology (BRIT), Nuclear Medicine Associations, Cancer Research UK, British Nuclear Medicine Society (BNMS), Spanish Society of Nuclear Medicine
(SEMN), Italian Association of Nuclear Medicine Molecular Imaging, French Society of Nuclear Medicine, Experts Interviews, and MarketsandMarkets Analysis
TABLE 2 EUROPE: ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
COUNTRY/REGION 2013 2014 2015-e 2020-p
CAGR
(2015-2020)
Germany xx.x xx.x xx.x xx.x xx.x%
U.K. xx.x xx.x xx.x xx.x xx.x%
Italy xx.x xx.x xx.x xx.x xx.x%
Spain xx.x xx.x xx.x xx.x xx.x%
RoE xx.x xx.x xx.x xx.x xx.x%
TABLE 3 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL
VOLUME, BY TYPE, 2013–2020 (THOUSAND)
TYPE 2013 2014 2015 2020
CAGR
(2015-2020)
Diagnostic xx.x xx.x xx.x xx.x xx.x%
Therapeutic xx.x xx.x xx.x xx.x xx.x%
SAMPLE TABLES

RELATED REPORTS
RELATED REPORTS
SR. NO. REPORT TITLE PUBLISHED DATE
1
Nuclear Medicine Equipment Market
by Product (SPECT (Hybrid SPECT, Standalone SPECT), hybrid PET,
Planar Scintigraphy), Application (Cardiology, Oncology Neurology) by
End user (Hospitals, Imaging Centers) - Global Forecasts to 2020
September 2015
2
Nuclear Medicine/Radiopharmaceuticals Market
by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta
Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) by Application
(Oncology, Thyroid, Cardiology) - Global Forecasts to 2020
July 2015
EUROPEAN NUCLEAR MEDICINE/
RADIOPHARMACEUTICALS MARKET
BY TYPE {DIAGNOSTIC (SPECT - TECHNETIUM, PET- F-18), THERAPEUTIC (BETA
EMITTERS – I-131, ALPHA EMITTERS, BRACHYTHERAPY – Y-90)},
BY APPLICATION (ONCOLOGY, THYROID, CARDIOLOGY)
sales@marketsandmarkets.com
www.marketsandmarkets.com

ABOUT MNM
MarketsandMarkets is a global market research and consulting company based in the U.S. It is World’s No. 2 in terms of
premium market research studies published annually. Serving as a business intelligence partner to Fortune 500 companies
across the world, it provides multi-client reports, company profiles, databases, and custom research services.
MarketsandMarkets covers seventeen industry verticals, including advanced materials, aerospace and defense, agriculture,
automotive and transportation, biotechnology, building and construction, chemicals, energy and power, food and beverages,
industrial automation, medical devices, mining, minerals and metals, packaging, pharmaceuticals, semiconductor and
electronics, and telecommunications and IT.
Copyright © 2015 MarketsandMarkets
All Rights Reserved. This document contains highly confidential information and is the sole property of MarketsandMarkets.
No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of MarketsandMarkets.
DISCLAIMER:
MarketsandMarkets strategic analysis services are limited publications containing valuable market information provided to
a select group of customers in response to orders. Our customers acknowledge, when ordering, that MarketsandMarkets
strategic analysis services are for our customers’ internal use and not for general publication or disclosure to third parties.
Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation.
MarketsandMarkets does not endorse any vendor, product or service depicted in its research publications. MarketsandMarkets
strategic analysis publications consist of the opinions of MarketsandMarkets’ research and should not be construed
as statements of fact. MarketsandMarkets disclaims all warranties, expressed or implied, with respect to this research, including
any warranties of merchantability or fitness for a particular purpose.
MarketsandMarkets takes no responsibility for any incorrect information supplied to us by manufacturers or users.
All trademarks, copyrights and other forms of intellectual property belong to their respective owners and may be protected
by copyright. Under no circumstance may any of these be reproduced in any form without the prior written agreement of
their owner.
No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written permission.
Reproduction and/or transmission in any form and by any means including photocopying, mechanical, electronic, recording
or otherwise, without the permission of the publisher is prohibited.
For information regarding permission, contact:
1-888-600-6441
sales@marketsandmarkets.com

European Nuclear Medicine/Radiopharmaceuticals Market: Increasing Preference for Spect and PET Scans | Market overview | Forecast Analysis.

Recommended

Recommended

More Related Content

What's hot

What's hot (19)

Similar to European Nuclear Medicine/Radiopharmaceuticals Market: Increasing Preference for Spect and PET Scans | Market overview | Forecast Analysis.

Similar to European Nuclear Medicine/Radiopharmaceuticals Market: Increasing Preference for Spect and PET Scans | Market overview | Forecast Analysis. (20)

Recently uploaded

Recently uploaded (20)

European Nuclear Medicine/Radiopharmaceuticals Market: Increasing Preference for Spect and PET Scans | Market overview | Forecast Analysis.